Akums Drugs & Pharmaceuticals LtdQ3 FY24
Akums Drugs & Pharmaceuticals Ltd Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹609P/E: 26.6Market Cap: ₹8.6K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →The company expects overall growth toward a better future with positive volume trends continuing (Page 13).
- →CDMO business saw an 11% volume decline in Q2 but is expected to stabilize and grow in H2 and FY26 (Pages 10-11).
- →API prices, which have impacted revenues, are expected to normalize by Q3 or Q4 FY25, potentially boosting financials (Page 9).
- →Export markets including Europe and Africa are key growth drivers, with dossiers filed and manufacturing setups underway; commercial benefits expected in a couple of fiscals, quicker ramp-up in Zambia (~18-24 months) (Pages 5, 7, 8).
- →Trade generic business is being scaled down but expected to reach positive monthly EBITDA by H2 FY25 (Page 11).
- →Continuous R&D investment aims to add new products and therapies to the pipeline to drive future growth (Page 13).
- →Market share in CDMO business is currently stable and expected to increase with new plant capacities coming online (Pages 9-11).
Margin guidance
Category 3- →Company expects growth driven by new product pipelines, R&D (400 scientists), and process improvements.
- →Anticipates volume growth in CDMO business to stabilize and grow by FY26; no loss of market share expected.
- →API business impacted by falling prices; EBITDA breakeven now expected 6 months after Q2 FY25, possibly delayed beyond Q4 FY25.
- →Export business (Europe, Africa, Zambia JV) expected to yield commercial benefits in next 2-3 years.
- →Margins impacted short-term by softer API prices, but stability is expected in H2 FY25 with potential normalization in Q3/Q4.
- →Trade generic segment being scaled down; expected to break even monthly by H2 FY25.
- →Long-term outlook positive with investments in injectables, new facilities, and new therapies such as patented sickle cell product and others.
- →Stakeholders including investors expected to benefit as company scales operations and market position globally.
3 more insights locked — sign up free to unlock
Fundraise plans
- →No explicit mention of any current or planned new fundraising through debt or equity in the transcript.
- →IPO proceeds have already been received and largely utilized till November 2024.
- →The company has a positive net cash flow of Rs. 341 crore and positive cash flow from operations (Rs. 71 crore for H1 September 2024).
- →Long-term credit rating improved to AA Stable by ICRA, indicating good financial health and borrowing capacity.
- →Management discusses ongoing investments in CAPEX and R&D funded from existing resources.
- →No stated plans for fresh debt or equity fundraising in the near term were disclosed during the call.
Order book
- →Akums Drugs and Pharmaceuticals Limited has a robust pipeline with over 350 dossiers pending in South-East Asia, African, Middle East, and European markets.
- →The company received more than 80 approvals in the first half of the fiscal year, indicating steady progress in order fulfillment.
- →They are expanding their product portfolio from oral solid dosage (OSD) to injectables, with new plants being commissioned in Europe and India.
- →Strong focus on filing dossiers in export markets, expecting commercial benefits mostly within the next 2 fiscal years, especially from Europe and Zambia.
- →The injectable facility at Haridwar is being commissioned in phases, adding to future manufacturing capacity.
- →Approximately 26 out of the top 30 Pharma companies in India are long-standing clients, indicating strong demand and ongoing orders.
- →Growth initiatives in new therapies and government-linked projects also imply a growing orderbook for the future.
Capex plans
Yes- →Land acquisition for Jammu plants completed; civil works to begin shortly with commercial production expected in FY26-27.
- →Continued investment in API R&D with over 80 scientists; Rs. 7 crore spent in H1 FY25 and a total of Rs. 30 crore till date.
- →Significant CAPEX of around Rs. 150 crore spent in H1 FY25 to build production capability.
- →New injectable facility in Haridwar started commercial production in Q2 with ampoule and SVP FFS lines operational; vial and lyophilized vial production to begin in Q3; LVP FFS line to be operational by Q4.
- →Expansion of glass ampoules, FFS ampoules, and lyophilization capacity underway to meet growing demand.
- →MoU signed with Government of Zambia for a joint venture to set up pharmaceutical manufacturing facility, expected to take 18-24 months to set up.
- →Filed 2 dossiers in Europe; building pipeline for European and other export markets.
How does Akums Drugs & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Akums Drugs & Pharmaceuticals Ltd
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
Want more stocks like Akums Drugs & Pharmaceuticals Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio